IN THE CLAIMS

1. (currently amended)A compound of formula 1



(1)

wherein

R^1

(i) is $-C_{1-10}$-alkyl, straight-chain or branched-chain, optionally mono- or polysubstituted by –OH, -SH,
$-NH_2$, $-NHC_{1-6}$-alkyl, $-N(C_{1-6}\text{-alkyl})_2$, $-NHC_{6-14}$-aryl,
$-N(C_{6-14}\text{-aryl})_2$, $-N(C_{1-6}\text{-alkyl})(C_{6-14}\text{-aryl})$, $-NO_2$,
-CN, -F, -Cl, -Br, -I, $-O-C_{1-6}$-alkyl, $-O-C_{6-14}$-aryl, $-S-C_{1-6}$-alkyl, $-S-C_{6-14}$-aryl, $-SO_3H$, $-SO_2C_{1-6}$-alkyl,
$-SO_2C_{6-14}$-aryl, $-OSO_2C_{1-6}$-alkyl, $-OSO_2C_{6-14}$-aryl,
-COOH, $-(CO)C_{1-5}$-alkyl, $-COO-C_{1-5}$-alkyl, $-O(CO)C_{1-5}$-alkyl, by a mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycle ~~carbocycles~~ with 3-14 ring members ~~or/and by mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-15 ring members and 1-6 heteroatoms, which are preferably N, O and S,~~

where the C_{6-14}-aryl groups and the carbocyclic ~~and heterocyclic~~ substituents ~~in turn~~ may optionally be substituted at least once ~~one or more times~~ by -C_{1-6}-alkyl, -OH, -NH_2, -NHC_{1-6}-alkyl, -$N(C_{1-6}$-alkyl$)_2$, -NO_2, -CN, -F, -Cl, -Br, -I, -O-C_{1-6}-alkyl, -S-C_{1-6}-alkyl, -SO_3H, -SO_2C_{1-6}-alkyl, -OSO_2C_{1-6}-alkyl, -COOH, -(CO)C_{1-5}-alkyl, -COO-C_{1-5}-alkyl or ~~or/and~~ –O(CO)C_{1-5}-alkyl, and wherein ~~where~~ the alkyl groups on the carbocyclic ~~and heterocyclic~~ substituents ~~in turn~~ may optionally be substituted ~~one or more times~~ at least once by –OH, -SH, -NH_2, -F, -Cl, -Br, -I, -SO_3H or ~~or/and~~ –COOH, or

(ii) is –C_{2-10}-alkenyl, mono- or polyunsaturated, straight-chain or branched-chain, optionally mono- or polysubstituted by at least one of –OH, -SH, -NH_2, -NHC_{1-6}-alkyl, -$N(C_{1-6}$-alkyl$)_2$, -NHC_{6-14}-aryl, -$N(C_{6-14}$-aryl$)_2$, -$N(C_{1-6}$-alkyl$)(C_{6-14}$-aryl), -NO_2, -CN, -F, -Cl, -Br, -I, -O-C_{1-6}-alkyl, -O-C_{6-14}-aryl, -S-C_{1-6}-alkyl, -S-C_{6-1}-aryl, -SO_3H, -SO_2C_{1-6}-alkyl, -SO_2C_{6-14}-aryl, -OSO_2C_{1-6}-alkyl, -OSO_2C_{6-14}-aryl, -COOH, -(CO)C_{1-5}-alkyl, -COO-C_{1-5}-alkyl or ~~or/and~~ -O(CO)C_{1-}-alkyl, by mono-, bi- or tricyclic saturated or mono- or a polyunsaturated carbocycle ~~carbocycles~~ with 3-14 ring members ~~or/and by mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-15 ring members and 1-6 heteroatoms, which are preferably N, O and S,~~

where the C_{6-14}-aryl groups and the carbocyclic ~~and heterocyclic~~ substituents in turn may optionally be substituted at least once ~~one or more times~~ by -C_{1-6}-alkyl, -OH, -NH_2, -NHC_{1-6}-alkyl, -$N(C_{1-6}$-alkyl$)_2$, -NO_2, -CN, -F, -Cl, -Br, -I, -O-C_{1-6}-alkyl, -S-C_{1-6}-alkyl, -SO_3H, -SO_2C_{1-6}-alkyl, -OSO_2C_{1-6}-alkyl, -COOH, -(CO)C_{1-5}-alkyl, -COO-C_{1-5}-alkyl or ~~or/and~~ –O(CO)C_{1-5}-alkyl,

and where the alkyl groups on the carbocyclic ~~and heterocylic~~ substituents ~~in turn~~ may optionally be substituted at least once ~~one or more times~~ by –OH, -SH, -NH_2, -F, -Cl, -Br, -I, -SO_3H or ~~or/and~~ –COOH,

R^2 is hydrogen or –C_{1-3}-alkyl,

R^3 is a hydroxyl group, and wherein

R^4 and R^5 may be identical or different and are hydrogen, -C_{1-6}-alkyl, -OH, -SH, -NH_2, -NHC_{1-6}-alkyl, -$N(C_{1-6}$-alkyl$)_2$, -NO_2, -CN, -SO_3H, -SO_3-C_{1-6}-alkyl, -COOH, -COO-C_{1-6}-alkyl, -O(CO)-C_{1-5}-alkyl, -F, -Cl, -Br, -I, -O-C_{1-6}-alkyl, -S-C_{1-6}-alkyl, or -phenyl ~~or pyridyl~~, where the phenyl substituent ~~or pyridyl substituents in turn~~ may optionally be substituted at least once ~~one or more times~~ by -C_{1-3}-alkyl, -OH, -SH, -NH_2, -NHC_{1-3}-alkyl, -$N(C_{1-3}$-alkyl$)_2$, -NO_2, -CN, -SO_3H, -SO_3C_{1-3}-alkyl, -COOH, -$COOC_{1-3}$-alkyl, -F, -Cl, -Br, -I, -O-C_{1-3}-alkyl, -S-C_{1-3}-alkyl, or ~~or/and~~ –O(CO)C_{1-3}-alkyl, and where the alkyl substituents in turn may optionally be substituted at least once ~~one or more times~~ by –OH, -SH, -NH_2, -F, -Cl, -Br, -I, -SO_3H, -SO_3C_{1-3}-alkyl, -COOH, -$COOC_{1-3}$-alkyl, -O-C_{1-3}-alkyl, -S-C_{1-3}-alkyl or ~~or/and~~ –O(CO)-C_{1-3}-alkyl, or a salt ~~thereof~~ thereof.

2. (previously presented) A compound as claimed in claim 1, having at least one asymmetric carbon atom in the D form, the L form and D,L mixtures, and in the case of a plurality of asymmetric carbon atoms also the diastereomeric forms.

3. (previously presented) A compound as claimed in claim 1, wherein R^2 is hydrogen or a methyl group.

4. (canceled)

5. (currently amended) A compound as claimed in claim 1, selected from the group consisting of:

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-chlorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide;

N-(1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,4-dichlorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[5-hydroxy-1-(3-nitrobenzyl)-indol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,6-difluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-(5-hydroxy-1-isobutylindol-3-yl)glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-(1-cyclopropyl-methyl-5-hydroxyindol-3-yl)glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[5-hydroxy-1-(4-hydroxybenzyl)-indol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-N-methyl-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide;

~~and~~ or a physiologically tolerated salt ~~salts~~ thereof.

6. (previously presented) The compound of claim 1 that is N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide.

Claims 7-15 (canceled)

16.(previously presented) A compound as claimed in claim 2 wherein R^2 is hydrogen or a methyl group.

17.(previously presented) The compound of claim 1 that is a physiologically acceptable salt of N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]glyoxylamide.

Claims 18-19 (canceled)

20.(currently amended) A compound as claimed in claim 1, wherein at least one of R^4 and R^5 is F, Cl, Br, or I ~~a halogen atom~~.

21. (new) A pharmaceutical composition comprising the compound as claimed in claim 1 and at least one of a conventional physiologically tolerated carrier, diluent or excipient.